Mastering the art of patient‑focused treatment
Pipeline/Trials
Our commitment to excellence
Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.
Program
Drug candidate
Indication
Pre-clinical
Phase 1
Phase 2
Phase 3
Orascovery
(P-gp inhibitor [encequidar] + ChemoRx agents)
Metastatic breast cancer
Angiosarcoma
Oral topotecan + encequidar
Solid tumors
Oral eribulin + encequidar
Solid tumors
Dual Inhibition
ATNX-04 (CYP/P-gp)
Multiple tumors
Src Kinase Inhibition
Tirbanibulin (KX2-391) ointment
Actinic keratosis
Psoriasis
Skin cancers
Tirbanibulin (KX2-391) oral
Liquid tumors
Ovarian cancer
KX2-361 (KX-02)
Glioblastoma
TCR-T Immunotherapy
TAEST16001
Multiple tumors
Arginine Deprivation Therapy
(PT-01) Pegtomarginase
Multiple tumors
Posted pipeline was current on January 2, 2020. Pipeline may not reflect changes in phase of development after January 2, 2020.
*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.
Clinical Platform
Orascovery
(P-gp inhibitor [encequidar] + ChemoRx agents)
Angiosarcoma
Oral topotecan + encequidar
Solid tumors
Oral eribulin + encequidar
Solid tumors
Clinical Platform
Dual Inhibition
ATNX-04 (CYP/P-gp)
Multiple tumors
Clinical Platform
Src Kinase Inhibition
Tirbanibulin (KX2-391) ointment
Actinic keratosis
Psoriasis
Skin cancers
Tirbanibulin (KX2-391) oral
Liquid tumors
Ovarian cancer
KX2-361 (KX-02)
Glioblastoma
Clinical Platform
TCR-T Immunotherapy
TAEST16001
Multiple tumors
Clinical Platform
Arginine Deprivation Therapy
(PT-01) Pegtomarginase
Multiple tumors
Posted pipeline was current on January 2, 2020. Pipeline may not reflect changes in phase of development after January 2, 2020.
*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.